

## DAFTAR PUSTAKA

1. Irawati D, Ekawanti A, Josafat A. Nutritional profile in Indonesian elderly subpopulation. *IJM. JKKI*. 2020;11(2):121–9.
2. Kaur D, Rasane P, Singh J, Kaur S, Kumar V, Mahato DK, *et al.* Aging: Overview and considerations for the development of geriatric foods. *Curr. Aging Sci.* 2019;12:1–13.
3. Setiati S, Laksmi PW, Aryana S, Sunarti S, Widajanti N, Dwipa L, *et al.* Frailty state among Indonesian elderly: prevalence, associated factors, and frailty state transition. *BMC Geriatr.* 2019;19:182.
4. Undang-undang Republik Indonesia nomor 13 Tahun 1998 tentang kesejahteraan lanjut usia.
5. The situation of the elderly in Indonesia and access to social protection programs: secondary data analysis. SMERU Research Report. 2020.
6. Setiati S, Harmurti K, Rooshoeroe AG. Proses menua dan implikasi kliniknya. Dalam : Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF (editor). *Buku Ajar Ilmu Penyakit Dalam*. Edisi VI. Jakarta : Pusat Penerbitan Ilmu Penyakit Dalam. 2014.
7. Merchant RA, Morley JE, Izquierdo M. Exercise, aging, and frailty: guidelines for increasing function. *J Nutr Health Aging*. 2021;25(4):405–9.
8. Fülöp T, Dupuis G, Witkowski JM, Larbi A. The role of immunosenescence in the development of age-related diseases. *Rev Inves Clin.* 2016;68:84–91.
9. Alberro A, Lopez AI, Cuesta MS, Matheu A, Vergara I, Otaegui D. Inflammaging markers characteristic of advanced age show similar levels with frailty and dependency. *Sci. Rep.* 2021;11:4358.
10. Gomes AT, Laffon B, Valdiglesias V, Gostner JM, Felder T, Costa C, *et al.* Exploring early detection of frailty syndrome in older adults: evaluation of oxi-

immune markers, clinical parameters and modifiable risk factors. *Antioxidants*.2021;10:1–21.

11. Saedil AA, Chow S, Vogrin S, Guillemin GJ, Duque G. Association between tryptophan metabolites, physical performance, and frailty in older persons. *Int. J. Tryptophan Res.* 2021;15:1–9.
12. Kanova M, Kohout P. Tryptophan: A unique role in the critically ill. *Int. J. Mol. Sci.* 2021;22(11714):1–21.
13. Saedil AA, Chow S, Vogrin S, Guillemin GJ, Duque G. Association between tryptophan metabolites, physical performance, and frailty in older persons. *Int. J. Tryptophan Res.* 2021;15:1–9.
14. Khosla S, Farr JN, Kirkland JL. Inhibiting cellular senescence: A new therapeutic paradigm for age-related osteoporosis. *J Clin Endocrinol Metab.* 2018;103(4):1282–90.
15. Salminen A. Role of indoleamine 2,3-dioxygenase 1 (IDO1) and kynurenine pathway in the regulation of the aging process. *Ageing Res. Rev.* 2022;75:1–13.
16. Sipahi H, Girgin G, Inanici F, Ariogul S, Sahin G, Baydar T. Tryptophan degradation and neopterin levels by aging. *Pteridines.* 2013;24(1):33–9.
17. Gomes AT, Laffon B, Valdiglesias V, Gostner JM, Felder T, Costa C, *et al.* Exploring early detection of frailty syndrome in older adults: evaluation of oxidative-immune markers, clinical parameters and modifiable risk factors. *Antioxidants.* 2021;10(1975):1–21.
18. Cruz-Jentoft AJ, Landi F, Topinkova E, Michel JP. Understanding sarcopenia as a geriatric syndrome. *Curr. Opin. Clin. Nutr. Metab. Care.* 2010;13:1–7.
19. Cruz-Jentoft A J, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, *et al.* Sarcopenia: European consensus on definition and diagnosis. Report of the European working group on sarcopenia in older people. *Age and Ageing Journal.* 2010;39: 412–23.

20. Aryana IGPS, Hapsari AAAR, Kuswardhani RAT. Myokine regulation as marker of sarcopenia in elderly. *Mol Cell Biomed Sci.* 2018;2(2):38-47.
21. Nielsen AR, Pedersen BK. The biological roles of exercise-induced cytokines: IL-6, IL-8 and IL-15. *Appl Physiol Nutr Metab.* 2007; 32. 833–9.
22. Quinn LS, Anderson BG, Bodey LS, Hanson TW. Serum and muscle Interleukin-15 level decrease in aging mice; correlation with declines in soluble Interleukin-15 receptor alpha expression. *Exp Gerontol.* 2010;45:106–12.
23. Triansyah F. Perbandingan kadar Miostatin dan Interleukin-15 serum pada pasien geriatri dengan pre sarkopenia, sarkopenia dan sarkopenia Berat. 2020.
24. Faller JW, Pereira DN, Souza S, Nampo FK, Orlandi FS, Matumoto S. Instruments for the detection of frailty syndrome in older adults: A systematic review. *PLoS ONE.* 2019;14(4):1–23.
25. Conroy S, Elliott A. The frailty syndrome. *Medicine.* 2016:1–4.
26. Thompson C, Taleban S. Incorporating frailty in the treatment program of elderly patients with gastrointestinal disease. *Curr Treat Options Gastro.* 2020;18:635–56.
27. Woolford SJ, Sohan O, Dennison EM, Cooper C, Patel HP. Approaches to the diagnosis and prevention of frailty. *Aging Clin Exp Res.* 2020;32:1629–37.
28. Pérez DM, Flores MS, Maseda A, López LL, Calenti JCM, Strasser B, *et al.* Frailty status in older adults is related to alterations in indoleamine 2,3-dioxygenase 1 and guanosine triphosphate cyclohydrolase I enzymatic pathways. *J Am Med Dir Assoc.* 2017; 18(12):1049–57.
29. Blasiak J. Senescence in the pathogenesis of age-related macular degeneration. *Cell. Mol. Life Sci.* 2020.1–17.
30. Ma L. Current situation of frailty screening tools for older adults. *J Nutr Health Aging.* 2018:1–8.

31. Xue QL. The frailty syndrome: definition and natural history. *Clin Geriatr Med.* 2011; 27(1):1–15.
32. Dent E, Lien C, Lim WS, Wong WC, Wong CH, *et al.* The asia-pacific clinical practice guidelines for the management of frailty. *JAMDA.* 2017;18:564–75.
33. Ortuno RR. An alternative method for frailty index cut-off points to define frailty categories. *Eur Geriatr Med.* 2013; 4(5):1–11.
34. Won CW. Diagnosis and management of frailty in primary health care. *Korean J Fam Med.* 2020;41:207–13.
35. Kojima G, Iliffe S, Taniguchi Y, Shimada H, Rakugi H, Walters K. Prevalence of frailty in Japan: A systematic review and meta-analysis. *J. Epidemiol.* 2017;27:347–53.
36. Thinuan P, Siviroj P, Lerttrakarnnon P, Lorga T. Prevalence and potential predictors of frailty among community-dwelling older persons in northern Thailand: A cross-sectional study. *Int.J.Environ.Res.Public Health.* 2020;17:1–13.
37. Thompson C, Taleban S. Incorporating frailty in the treatment program of elderly patients with gastrointestinal disease. *Curr Treat Options Gastro.* 2020;18:635–56.
38. Wleklík M, Uchmanowicz I, Jankowska EA, Vitale C, Lisiak M, Drozd M, *et al.* Multidimensional approach to frailty. *Front. Psychol.* 2020;11(564):1–11.
39. Wou F, Conroy S. The frailty syndrome. *Medicine.* 2013;14(1):13–15.
40. Woolford SJ, Sohan O, Dennison EM, Cooper C, Patel HP. Approaches to the diagnosis and prevention of frailty. *Aging Clin Exp Res.* 2020;32:1629–37.
41. Dent E, Morley JE, Cruzjentoft AJ, Woodhouse L, Manas LR, Fried LP, *et al.* Physical frailty: ICFSR international clinical practice guideline for identification and management. *J Nutr Health Aging.* 2019;23(9):771–87.

42. Putra IGAW, I Gusti Putu Suka Aryana , Astika IN, Kuswardhani RAT, Putrawan IB, Rai Purnami KR. Prevalensi sarkopenia dan frailty di desa Pedawe, Mangupura, Serai dan Songan. *ISM*. 2020;11(2):546–50.
43. Rahmadani IR, Dwipa L, Pratiwi YS. Karakteristik lanjut usia dengan sindroma frailty berdasarkan kuesioner Frailty Index–40 (FI–40) di Panti Werdha Bandung. *Int. j. med. health res*. 2018;2(2).756–63.
44. Mahayuni NMA, Kuswardani RAT. Frailty dan activity daily life pada lanjut usia laki-laki di kelurahan Pemecutan, kecamatan Denpasar Barat, Kota Denpasar, Bali. *Udayana. J. Intern. Med*. 2020;4(2):36–9.
45. Pengpid S, Peltzer K. Prevalence and associated factors of frailty in community-dwelling older adults in Indonesia, 2014–2015. *Int. J. Environ. Res. Public Health*. 2020;17(10):1–13.
46. Drew W, Wilson D, Sapey E. Frailty and the immune system. *JARH*. 2017;2(1):1–14.
47. Clegg A, Young J. The frailty syndrome. *Clin Med*. 2011;11(1):72–5.
48. Fulop T, Larbi A, Witkowski JM, McElhaney J, Loeb M, Mitnitski A, *et al*. Aging, frailty and age-related diseases. *Biogerontology*. 2010;11:547–63.
49. Satake S, Arai H. Chapter 1 Frailty: Definition, diagnosis, epidemiology. *Geriatr Gerontol Int*. 2020;20(1):7–13.
50. Prat MS, Papiol M, Vico J, Palomera E, Sist X, Cabre M. Factors associated with frailty in community-dwelling elderly population. A cross-sectional study. *Eur. Geriatr. Med*. 2016;7:531–7.
51. Fülöp T, Larbi A, Witkowski JM. Human inflammaging. *Gerontology*. 2018:1–10.
52. Seto E, Setiati S, Laskmi P, Tamin T. Diagnostic test of a scoring system for frailty syndrom in the elderly according to cardiovascular health study, study of osteoporotic fracture and comprehensive geriatric assessment based fracture

- and comprehensive geriatric assessment based FI 40. *Act Med Indones-Indones J Intern Med.* 2015;47(3):183–7.
53. Clegg A, Young J, Iliff S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet.* 2013;381:752–62.
54. Won CW. Diagnosis and management of frailty in primary health care. *Korean J Fam Med.* 2020;41:207–13.
55. Thomas R, Wang W, Su DM. Contributions of age-related thymic involution to immunosenescence and inflammaging. *Immun. Ageing.* 2020;17(2):1–17.
56. Feehan J, Tripodi N, Apostolopoulos V. The twilight of the immune system: The impact of immunosenescence in aging. *Maturitas.* 2021;147:7–13.
57. Kuzuya M. Process of physical disability among older adult contributing of frailty in the super aged society. *Nagoya J. Med.* 2012;74:31–7.
58. Ramprasath T, Han YM, Zhang D, Yu CJ, Zou MH. Tryptophan catabolism and inflammation: A novel therapeutic target for aortic diseases. *Front. Immunol.* 2021;12(731701):1–11.
59. Badawy AA. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. *Int. J. Tryptophan Res.* 2017;10:1–20.
60. Wang Q, Liu D, Song P, Zou MH. Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. *Front Biosci.* 2015;20:1116–43.
61. Kindler J, Lim CK, Weickert CS, Boerrigter D, Galletly C, Liu D, *et al.* Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. *Mol. Psychiatry.* 2020;25:2860–72.
62. Sorgdrager FJH, Naudé PJW, Kema IP, Nollen EA, Deyn PP. Tryptophan metabolism in inflammaging: from biomarker to therapeutic target. *Front. Immunol.* 2019;10(2565):1–8.

63. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat Rev Cardiol.* 2018;15(9):505-22.
64. Zhai L, Ladomersky E, Bell A, Dussold C, Cardoza K, Qian J *et al.* Quantification of IDO1 enzyme activity in normal and malignant tissues. *Methods Enzymol.* 2019.
65. Jang IY, Park JH, Kim JH, Lee S, Lee E, Lee JY, *et al.* The association of circulating kynurenine, a tryptophan metabolite, with frailty in older adults. *AGING.* 2020;12(21):22253–65.
66. Geisler S, Mayersbach P, Becker K, Schennach H, Fuchs D, Gostner JM. Serum tryptophan, kynurenine, phenylalanine, tyrosine and neopterin concentrations in 100 healthy blood donors. *Pteridines.* 2015; 26(1):31–36.
67. Pérez DM, Flores MS, Maseda A, López LL, José C. Millán-Calenti JCM, Strasser B, *et al.* Frailty status in older adults is related to alterations in indoleamine 2,3-dioxygenase 1 and guanosine triphosphate cyclohydrolase I enzymatic pathways. *Journal of the American Medical Directors Association. J Am Med Dir Assoc.* 2017;18(12):1049–57.
68. Gomes AT, Laffon B, Valdiglesias V, Gostner JM, Felder T, Costa C, *et al.* Exploring early detection of frailty syndrome in older adults: evaluation of ox-immune markers, clinical parameters and modifiable risk factors. *Antioxidants.* 2021;10(1975):1–21.
69. Wenninger J, Meinitzer A, Holasek S, Schnedl WJ, Zelzer S, Mangge H, *et al.* Associations between tryptophan and iron metabolism observed in individuals with and without iron deficiency. *Sci.Rep.* 2019;9:14548.
70. Schroëksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. *Clin. Chim.* 2006:82–90.
71. Gyamfi CG, Snyman T, Makhathini L, Ot wombe K, Darboe F, Nicholson AP, *et al.* *Int. J. Infect. Dis.* 2020; 99: 441–8.

72. Perera PY, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. *Microbes Infect.* 2012;14:247–61.
73. Gomasasca M, Banfia G, Lombardi G. Myokines: The endocrine coupling of skeletal muscle and bone. *Myokines and bone.* 2019:1–64.
74. Quinn LS, Anderson BG, Bodey LS, Hanson TW. Serum and muscle interleukin-15 levels decrease in aging mice: Correlation with declines in soluble interleukin-15 receptor alpha expression. *Exp. Gerontol.* 2010;45:106–12.
75. Aryana IGPS, Hapsari AAAR, Kuswardhani RAT. Myokine regulation as marker of sarcopenia in elderly. *Mol Cell Biomed Sci.* 2018;2(2):38–47.
76. Fiore PF, Matteo S, Tumino N, Mariotti FR, Pietra G, Ottonello S, *et al.* Interleukin-15 and cancer: some solved and many unsolved questions. *J Immunother Cancer.* 2020;8:e001428.
77. Yalcin A, Silay K, Balik AR, Avcioglu G, Aydin AS. The relationship between plasma interleukin-15 levels and sarcopenia in outpatient older people. *Aging Clin Exp Res.* 2017:1–8.
78. Aryana IGPS. Role of Interleukin-15 in sarcopenia: future new target therapy. *Int J Geriatr Gerontol.* 2017;1:1-8.
79. Quinn LS, Anderson BG, Strait-Bodey L, Strout AM, Argilles JM. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. *Am J Physiol Endocrinol Metab.* 2009;296:191-202.
80. Rahmadani IR, Dwipa L, Pratiwi YS. Karakteristik lanjut usia dengan sindroma frailty berdasarkan kuesioner Frailty Index–40 (FI–40) di Panti Werdha Bandung. *Int. j. med. health res.* 2018;2(2).756–63.
81. Bano G, Trevisan C, Carraro S, Solmi M, Luchini C, Stubbs B *et al.* Inflammation and sarcopenia: a systematic review and meta-analysis. *Maturitas Journal.* 2017;96:10–15.



82. Hyödynmaa J. Effect of intrinsic aerobic capacity, aging and physical activity on Interleukin-15 protein level in serum and skeletal muscle. *Spring Exercise Physiol.* 2015;1:1-17.
83. Marzetti E, Carter CS, Wohlgemuth SE, Lees AH, Giovannini S, Anderson B *et al.* Changes in IL-15 expression and death-receptor apoptotic signalling in rat gastrocnemius muscle with aging and life-long calorie restriction. *Mech Ageing Dev.* 2009;130:272–80.
84. Hingorjo MR, Zehra S, Saleem S, Qureshi MA. Serum Interleukin-15 and its relationship with adiposity Indices before and after short-term endurance exercise. *Pak J Med.* 2018;34(5):1125–31.
85. Antuña E, Vega CC, Millo JC, Potes Y, Caballero B, Naredo IV *et al.* Inflammaging: implications in sarcopenia. *Int. J. Mol. Sci.* 2022;23:1–24.
86. Ye J. Beneficial metabolic activities of inflammatory cytokine interleukin 15 in obesity and type 2 diabetes. *Inflammation and obesity.* 2015:1-7.
87. Hingorjo MR, Zehra S, Saleem S, Qureshi MA. Serum Interleukin-15 and its relationship with adiposity Indices before and after short-term endurance exercise. *Pak J Med.* 2018;34(5):1125–31.
88. Tamura Y, Watanabe K, Kantani T, Hayashi J, Ishida N, Kaneki M. Upregulation of circulating IL-15 by treadmill running in healthy individuals: Is IL-15 an endocrine mediator of the beneficial effects of endurance exercise?. *Endocrine Journal.* 2011;58(3):211-15.
89. Prado GH, Sardeli AV, Lord J, Cavaglieri CR. The effects of ageing, BMI and physical activity on blood IL-15 levels: A systematic review and meta-analyses. *Exp Gerontol.* 2022;15:168.
90. Uyainah A, Bahar A, Pramantara DP, Wahyudi ER, Harirnurti K, Legiawati L, *et al.* Management of frailty as a new geriatric giant: How to deal with dilemmatic health problems in elderly patient. *Prosiding Temu Ilmiah Geriatri* 2015:1–159.

91. Tan LF, Lim ZY, Choe R, Seetharaman S, Merchant R. Screening for frailty and sarcopenia among older persons in medical outpatient clinics and its associations with healthcare burden. *JAMDA*. 2017;1–5.
92. Chen S, Honda T, Chen T, Narazaki K, Haeuchi Y, Supartini A, Kumagai S. Screening for frailty phenotype with objectively-measured physical activity in a west Japanese suburban community: evidence from the Sasaguri Genkimon Study. *BMC Geriatrics*. 2015;15:36.
93. Corbi G, Cacciatore F, Komici K, Rengo G, Vitale DF, Furgi G *et al*. Interrelationships between Gender, Frailty and 10-Year Survival in older italian Adults: an observational longitudinal study. *Sci. Rep.* 2019;9:18416.
94. Rensa, Setiati S, Laksmi PW, Rinaldi I. Factors sssociated with physical frailty in elderly women with low Socioeconomic status in urban communities: A cross-sectional study. *Indones. J. Intern. Med.* 2019;51(3):220–9.
95. Trevisan C, Veronese N, Maggi S, Baggio G, Toffanello ED, Zambon S, *et al*. Factors influencing transition between frailty states in elderly adults: the Progetto Veneto Anziani longitudinal study. *J Am Geriatr Soc.* 2017;65:179–84.
96. Wei K, Thein FS, Nyunt MSZ, Gao Q, Wee SL, NG TP. Nutritional and frailty state transition in the Singapore longitudinal aging study. *J Nutr Health Aging.* 2018;22(10):1221–7.
97. Eyigor S, Kutsal YG, Duran E, Huner B, Paker N, Durmus B *et al*. Frailty prevalence and related factors in the older adult—FrailTURK Project. *AGE.* 2015;37:1–15.
98. Carneiro JA, Cardoso RR, Durães MS, Guedes MCA, Santos FL, Costa FM *et al*. Frailty in the elderly: prevalence and associated factors. *Rev Bras Enferm.* 2017;70(4):747–52.

99. Woo J, Zheng Z, Leung J, Chan P. Prevalence of frailty and contributory factors in three Chinese populations with different socioeconomic and healthcare characteristics. *BMC Geriatr.* 2015;15:163–74.
100. Esquinas EG, Garcia FJ, Munoz LM, Carnicero JA, Castillon PG, Gonzales-Colaco MG, *et al.* Obesity, fat distribution, and risk of frailty in two population-based cohorts of older adults in Spain. *Obesity.* 2015;23:847–55.
101. Rodrigues RA, Fhon JR, Pontes ML, Silva AO, Haas VJ, Santos JL. Frailty syndrome among elderly and associated factors: comparison of two cities. *Rev. Latino-Am. Enfermagem.* 2018;26:1–10.
102. Pinheiro HA, Mucio AA, Oliveira LF. Prevalence and factors associated with the frailty syndrome in older adults in the Brazilian federal district. *Geriatr Gerontol Aging.* 2020;14(1):8–14.
103. Lamana A, Ortiz AM, Gracia JM, Sánchez BD, Novalbos J, Vicuna RG *et al.* Characterization of serum interleukin-15 in healthy volunteers and patients with early arthritis to assess its potential use as a biomarker. *Eur. Cytokine Netw.* 2010; 21(3):186-94.
104. Agus A, Agus S, Suka A. Interleukin-15 is a significant predictor of sarcopenia in human immunodeficiency virus infected patients on antiretroviral therapy: A cross-sectional study. *Asian Pac. J. Trop. Med.* 2022; 15(8): 361–6.
105. Valdiglesias V, Marcos-Pérez D, Lorenzi M, Onder G, Gostner JM, Strasser B, *et al.* Immunological alterations in frail older adults: a cross sectional study. *Exp Gerontol.* 2018;112:119–26.
106. Pérez DM, Flores MS, Maseda A, López LL, José C. Millán-Calenti JCM, Strasser B, *et al.* Frailty status in older adults is related to alterations in indoleamine 2,3-dioxygenase 1 and guanosine triphosphate cyclohydrolase I enzymatic pathways. *Journal of the American Medical Directors Association.* *J Am Med Dir Assoc.* 2017;18(12):1049–57.

107. Shirooka H, Nishiguchi S, Fukutani N, Adachi D, Tashiro Y, Hotta T *et al.* Association between comprehensive health literacy and frailty level in community-dwelling older adults: A cross-sectional study in Japan. *Geriatr Gerontol Int.* 2016:1–6.

108. Valdiglesias V, Flores MS, Maseda A, López LL, Pérez DM, Cortón AL, *et al.* Immune biomarkers in older adults: Role of physical activity. *J. Toxicol. Environ.* 2017:1–15.

109. Gold AB, Herrmann N, Swardfager W, Black SE, Aviv RI, Tennen G, *et al.* The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment. *J. Neuroinflammation.* 2011;8:17.

